![](https://cdn.prod.website-files.com/64da88f95d252fd5a4415eda/65203a3182114a41b5f0526d_artigo6-img4.jpg)
FIGURE 1Three-dimensional models in microcomputed tomography (microCT) images before and after removal of intracanal medication based on (A) bioceramic compounds - BIO-C® Temp (Angelus, Londrina, Paraná, Brazil) and (B) calcium hydroxide - Ultracal XS (Ultradent Products Inc., SouthJordan, UT, USA). In red (I): root canal filled with intracanal medication. Inblue (II): intracanal medication remaining after removal with a final instrument and conventional irrigation with sodium hypochlorite. (III) Overlapping of images before and after the removal of intracanal medication.
TABLE 1Mean ± standard deviation and minimum andmaximum percentage value (%) of the remaining volume of intracanal medication (BIO-C® Temp and Ultracal XS) after using the last instrument and conventionalirrigation with 2.5% sodium hypochlorite and 17% EDTA for three minutes.
![](https://cdn.prod.website-files.com/64da88f95d252fd5a4415eda/6553a75e51c8601c265eb069_artigo5_eng-tabela-1.jpg)
TABLE 2Mean and standard deviation of bond strength values (Mpa) found for the push-out test in groups according to intracanal medication (BIO-C® Temp or Ultracal XS) and root canal sealer (AH Plus and BIO-C® Sealer).
![](https://cdn.prod.website-files.com/64da88f95d252fd5a4415eda/6553a75f2d2ab77881e954ae_artigo5_eng-tabela-2.jpg)
TABLE 3. Mean and standard deviation of the bond strength values (Mpa) found for the push-out test of the root thirds (cervical, middle, and apical) according to the intracanal medication (BIO-C® Temp or Ultracal XS) and root canal filling (AH Plus and BIO-C® Sealer).
![](https://cdn.prod.website-files.com/64da88f95d252fd5a4415eda/6553a75f495a1f6b72f46d08_artigo5_eng-tabela-3.jpg)
Resultados:
Experiment #1: Determining the remaining volume of intracanal medications
The t-test showed a statistically significant difference in the percentage of remaining intracanal medication volume (p < 0.0001) (Table 1), with a lower amount of intracanal remnant of the bioceramic composite-based medication (BIO-C® Temp) (1.77 ± 0.86) when compared to the calcium hydroxide-based medication (Ultracal XS) (10.47 ± 5.78), regardless of a third of the tooth evaluated.
Qualitative analysis of three-dimensional models and axial sections of the distal root before and after intracanal medication removal revealed a medication remnant in both products tested (Figure 1). When the remaining intracanal medication was compared in terms of chemical composition, it was clear that the medication based on bioceramic compounds (BIO-C® Temp) remained homogeneous and regular, particularly in the apical third (Figure 1A). In contrast to the calcium hydroxide-based intracanal medication.
Experiment #2: Bond strength test
The two-factor analysis of variance showed a statistically significant difference for the factors intracanal medication and root third and for the interaction of the factors intracanal medication x root third (p<0.0001). With regard to intracanal medication, it was observed that teeth that received intracanal treatment with a medication based on bioceramic compounds (BIO-C® Temp) and were filled with bioceramic sealer (BIO-C® Sealer) had higher bond strength values (3.70 ± 1. 22) when compared to teeth that received bioceramic-based medicaments and were filled with epoxy resin-based sealer (AH Plus) (2.15 ± 1.07), or calcium hydroxide-based medicament (Ultracal XS) and filled with bioceramic (3.18 ± 1.09) or epoxy resin-based sealer (AH Plus) (2.11 ± 1.02) (p < 0.001) (Table 2).
In reference to the root thirds, the cervical third exhibited higher bond strength values than the middle third (p < 0.001), with the middle third showing higher bond strength values (p < 0.001), and irrespective of the intracanal medication and cement (Table 3).
Experiment #3: Adhesive interface quality
![](https://cdn.prod.website-files.com/64da88f95d252fd5a4415eda/65203f808d3d382c93500029_artigo5_img-1.jpg)
FIGURE 5Light micrographs showing portions of capsule from sections subjected to immunohistochemistry for IL-10 detection (brown/yellow color) and counterstained with hematoxylin. It can be seen that few immunolabeled cells are present in the capsules of all groups, especially at 7 days (A-C). In all groups, obvious immunolabeling is present in mast cells (MC). Arrows: inflammatory cells; BV: blood vessels; material particles: arrowheads. Bars: 18 μm. (M) The graph shows the values (expressed as mean ± standard deviation) of the numerical density of cells immunolabeled with IL-10 in the capsules. In each period, the comparison between the groups is indicated by superscript letters; different letters = significant difference. The superscript numbers indicate the analysis of each group over time; different numbers = significant difference. Tukey's test (p ≤0.05).
In specimens in which intracanal medication (BIO-C® Temp) and bioceramic-based sealer (BIO-C® Sealer) were used, there was better adaptation of the filling material to the root dentin, also in polar areas (Figure 3), areas with juxtaposition of the adhesive interface and fewer interfacial gaps between sealer/dentin; and when they did occur, the gaps were smaller than in the other groups.